Tag Archives: Orencia

October, 2018

July, 2017

January, 2016

  • 8 January

    Mylan Partners with Momenta to Develop Six Biosimilar Products

    HERTFORDSHIRE, England and PITTSBURGH, Jan. 8, 2016 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has entered into an exclusive global collaboration agreement with Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) to develop, manufacture and commercialize six of Momenta’s current biosimilar candidates, including Momenta’s biosimilar candidate, ORENCIA® (abatacept). Mylan …